Related Experiment Videos
Alvimopan, a selective peripherally acting mu-opioid antagonist
1Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER) Program, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. camilleri.michael@mayo.edu
Neurogastroenterology and Motility
|March 25, 2005
Summary
Alvimopan, a peripherally acting mu-opioid antagonist, effectively manages postoperative ileus and opioid-induced constipation. It offers a solution for gastrointestinal motility disorders in patients using opiate analgesics.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Postoperative ileus and opioid-induced constipation are common clinical issues.
- Existing treatments for these gastrointestinal motility disorders have limitations.
Purpose of the Study:
- To review the pharmacology of alvimopan.
- To evaluate the clinical evidence for alvimopan in gastroenterology.
Main Methods:
- Literature review of basic and applied pharmacology.
- Analysis of current clinical evidence for alvimopan.
Main Results:
- Alvimopan is a peripherally acting mu-opioid antagonist.
- Evidence supports its use in managing postoperative ileus and opioid-induced gastrointestinal motility disorders.
Conclusions:
- Alvimopan addresses a clinical need for effective treatments.
- It shows promise for managing specific gastrointestinal motility issues in patients on opiate analgesics.